PPAR-γ signaling in nonalcoholic fatty liver disease: Pathogenesis and therapeutic targets
H Chen, H Tan, J Wan, Y Zeng, J Wang… - Pharmacology & …, 2023 - Elsevier
Non-alcoholic fatty liver disease (NAFLD), currently the leading cause of global chronic liver
disease, has emerged as a major public health problem, more efficient therapeutics of which …
disease, has emerged as a major public health problem, more efficient therapeutics of which …
PPAR-γ signaling in nonalcoholic fatty liver disease: Pathogenesis and therapeutic targets.
H Chen, H Tan, J Wan, Y Zeng, J Wang… - Pharmacology & …, 2023 - europepmc.org
Non-alcoholic fatty liver disease (NAFLD), currently the leading cause of global chronic liver
disease, has emerged as a major public health problem, more efficient therapeutics of which …
disease, has emerged as a major public health problem, more efficient therapeutics of which …
PPAR-γ signaling in nonalcoholic fatty liver disease: Pathogenesis and therapeutic targets
H Chen, H Tan, J Wan, Y Zeng… - Pharmacology & …, 2023 - pubmed.ncbi.nlm.nih.gov
Non-alcoholic fatty liver disease (NAFLD), currently the leading cause of global chronic liver
disease, has emerged as a major public health problem, more efficient therapeutics of which …
disease, has emerged as a major public health problem, more efficient therapeutics of which …